Boston Scientific (BSX) Total Current Liabilities (2009 - 2026)

Boston Scientific (BSX) has 18 years of Total Current Liabilities data on file, last reported at $4.6 billion in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 9.63% year-over-year to $4.6 billion; the trailing twelve-month figure through Mar 2026 stood at $4.6 billion (down 9.63% YoY), and the FY2025 full-year result was $5.4 billion, down 15.0% from the prior year.
• Total Current Liabilities declined to $4.6 billion in Q1 2026, from $5.4 billion in the prior quarter.
• In the past five years, Total Current Liabilities ranged from a high of $6.4 billion in Q4 2024 to a low of $3.5 billion in Q3 2022.
• A 5-year average of $4.8 billion and a median of $4.9 billion in 2024 frame the typical range for Total Current Liabilities.
• Across the five-year window, Total Current Liabilities increased 29.72% in 2024 and slipped 15.0% in 2025, its largest moves.
• Tracing BSX's Total Current Liabilities over 5 years: stood at $3.8 billion in 2022, then climbed by 29.71% to $4.9 billion in 2023, then increased by 29.72% to $6.4 billion in 2024, then retreated by 15.0% to $5.4 billion in 2025, then declined by 15.96% to $4.6 billion in 2026.
• Business Quant data shows BSX's Total Current Liabilities at $4.6 billion in Q1 2026, $5.4 billion in Q4 2025, and $5.3 billion in Q3 2025.